Compare iShares 7-10 Year Treasury Bond ETF (IEF) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 7-10 Year Treasury Bond ETF vs TG Therapeutics Inc — how do they compare? iShares 7-10 Year Treasury Bond ETF trades at $93.12, while TG Therapeutics Inc trades at $52.7 (market cap $8.26B). The key difference: TG Therapeutics Inc is trading nearer its 52-week high, iShares 7-10 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| IEF | TGTX | |
|---|---|---|
52-Week High | $97.99 | $59.06 |
52-Week Low | $93.11 | $26.39 |
Market Cap | — | $8.26B |
Sector | — | Health |
Enterprise Value | — | $8.50B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEF trades at $93.31, down 0.56% on the day amid a bearish technical outlook with moving averages signaling sell pressure. Recent dividends of $0.31-$0.32 per share reflect income stability, while news highlights bond ETF competition and Federal Reserve uncertainty. The asset faces headwinds from rising rate hike expectations and inflation concerns, with technical indicators showing neutral oscillators but bearish trend strength.
The outlook for IEF remains cautious due to potential Fed tightening and bond market volatility. Investment appeal hinges on income generation from dividends, but risks include interest rate sensitivity and macroeconomic shifts. Investors should weigh yield advantages against duration risk in a fluctuating rate environment.
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares 7-10 Year Treasury Bond ETF
The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity of greater than or equal to seven years and less than ten years. The fund will invest at least 80% of its assets in the component securities of the underlying index, and the fund will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index.
Read more on IEF →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
